MAXCYTE, INC.

For the period ended Jun 30, 2026. Filed Aug 13, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 13, 2026

MXCT$1.13-13.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations

Unaudited Condensed Consolidated Statements of Operations** and Comprehensive Loss**

(in thousands, except share and per share amounts)


· · Three Months Ended June 30, · · Six Months Ended June 30,
· · 2026 · · 2025 · · 2026 · · 2025
Revenue	$7,271	$8,507	$16,922	$18,897
Cost of goods sold	1,675	1,519	3,244	3,016
Gross profit	5,596	6,988	13,678	15,881

Operating expenses:
Research and development	4,253	6,269	8,110	12,172
Sales and marketing	3,364	5,786	6,792	11,484
General and administrative	7,258	8,080	13,224	16,606
Depreciation and amortization	953	1,080	1,969	2,141
Total operating expenses	15,828	21,215	30,095	42,403
Operating loss	(10,232)	(14,227)	(16,417)	(26,522)

Other income:
Interest income	1,358	1,870	2,793	3,904
Total other income	1,358	1,870	2,793	3,904
Loss before income taxes	(8,874)	(12,357)	(13,624)	(22,618)
Provision for income taxes	—	—	—	—
Net loss	(8,874)	(12,357)	(13,624)	(22,618)
Other comprehensive income	—	—	—	—
Comprehensive loss	$(8,874)	$(12,357)	$(13,624)	$(22,618)
Basic and diluted net loss per share	$(0.08)	$(0.12)	$(0.13)	$(0.21)
Weighted-average shares outstanding, basic and diluted	106,822,633	106,403,540	106,848,715	106,178,262

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.